ClinicalTrials.gov
public full text
Public Domain
Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer
The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every week in the treatment of patients with advanced ovarian cancer that is resistant to platinum-based chemotherapy.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- SGI-110 in Combination With Carboplatin in Ovarian Cancer#839915
- Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer#1363818
- Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma#883867
- Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer#1440238
- Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)#1259227
Record · ID 1484192
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive